1. Scrip
  2. >>Business
  3. >>Commercial Strategy

Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder

Lecanemab Phase III Readout Next Major Milestone

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.

Sailing yacht control wheel and implement
Biogen is trying to navigate its way back to revenue growth • Source: Shutterstock

Biogen, Inc.’s revenue is sinking and its next opportunity to right the ship is the Eisai Co., Ltd.-partnered lecanemab. However, the idea that it can steer the company toward major revenue growth with an amyloid-targeting therapy for Alzheimer’s disease after the spectacular demise of Aduhelm (aducanumab) and multiple other recent setbacks may not float with investors.

Biogen closed down 5.8% at $207.49 on 20 July even after the company reported second quarter financial results that exceeded...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.